The offer was completed on October 2 after raising $16.4 million to fund Kazia’s participation in the GBM AGILE pivotal study in glioblastoma.
This entitlement offer attracted strong support from institutional shareholders with all eligible accelerated holders participating, and an overall take-up by those parties of approximately 70%.
Change of director's interests
Chairman and non-executive director Iain Ross acquired 125,000 shares at 80 cents each in a direct interest, increasing the total amount of securities held to 945,001 shares.
Chief executive officer and executive director James Garner acquired 62,500 shares, increasing his stake in a direct interest to 362,500 shares.
Non-executive director Steven Coffey also acquired 62,500 shares in an indirect interest, increasing the total number of securities held in that interest to 402,500 shares.
Non-executive director Bryce Carmine also purchased 62,500 shares increasing his total number of securities to 352,692 shares.